Edinburgh Biosciences (EBS) has secured a series of international patents, in the US, Europe and Australia, as the eye care technology specialist company starts its final clinical trial before seeking regulatory approval.

EBS aims to improve the pathway of care for cataract patients, taking cataract treatment from the operating theatre onto the high street.

The company’s CEO, Graham Bell, said: “The patents are a significant step for the business, coming on the back of ongoing clinical trials which continue to provide positive outcomes, with reduced cataract density and improved vision overall.  The consultant ophthalmologists running the trials are excited about the potential beneficial impact of the EBS technology, so we move to our final clinical trial with great confidence.”

EBS’s LEDINBIO device deploys low intensity LED light for diagnosis, monitoring and treatment.  Over 20 million cataract operations took place worldwide in 2020, with the technology being developed by EBS making treatment delivery up to 90% quicker, with a significant reduction in cost per patient and deliverable in a high street clinical setting.

Last year, EBS signed a major international licensing and equity investment deal in China with Haoguang, a wholly-owned subsidiary of Boye Biotech.

Recommended

• DIGIT Movers and Shakers | June 2022
• Online Safety Bill: What are Ofcom’s new powers to fight child abuse material?
• Skyscanner co-founder backs Edinburgh ‘work-surfing’ startup, Swurf

EBS is targeting the European, UK and Chinese markets in its first phase of commercialisation, and plans to sell its technology to clinical optometry and ophthalmology providers, and other eye and healthcare industry players.

EBS’s CEO Graham Bell previously led corporate development, and mergers and acquisitions at NASDAQ-listed University of Dundee spin-out Cyclacel Pharmaceuticals, while Chairman David Quigley, a qualified optometrist and joint venture partner with Specsavers Opticians in Scotland, also chairs Optometry Scotland tasked with representing the community eye care sector to the Scottish Government.

The company’s Series A investment round process is being managed by Manchester-based advisory firm, Oyster Venture Partners, which specialises in supporting the life science, healthcare and healthtech sectors.

EBS will be presenting at the Campden Wealth MedTech Investing Europe Forum in Lausanne, Switzerland, on 11-12 July.

Get the latest news from DIGIT direct to your inbox

Our newsletter covers the latest technology and IT news from Scotland and beyond, as well as in-depth features and exclusive interviews with leading figures and rising stars.

To subscribe, click here.